Search results
Results from the WOW.Com Content Network
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1 ]
Repaglinide (trade name Prandin) [2] gained US Food and Drug Administration approval in 1997. Other drugs in this class include nateglinide (Starlix) [ 3 ] and mitiglinide (Glufast). Side effects
Repaglinide (Prandin) can help the body regulate the amount of glucose in the blood by stimulating the pancreas to release insulin before meals. In some cases, the baseline glucose levels are too high as well and insulin is required. MODY2 is an autosomal dominant condition. Autosomal dominance refers to a single, abnormal gene on one of the ...
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial". [1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing ...
Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin. [6] (subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.
Repaglinide (Prandin) [61] Sirolimus (Rapamycin, Rapamune) [83] Tamoxifen (Nolvadex): Tamoxifen is metabolized by CYP2D6 into its active metabolite 4-hydroxytamoxifen. Grapefruit juice may potentially reduce the effectiveness of tamoxifen. [84] Trazodone (Desyrel): Little or no interaction with grapefruit juice. [85]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Mitiglinide (INN, [1] trade name Glufast) is a drug for the treatment of type 2 diabetes. [2]Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.